URGN - UroGen Pharma Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
42.455
-0.535 (-1.24%)
As of 2:54PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close42.990
Open43.450
Bid42.270 x 1000
Ask42.570 x 1400
Day's Range42.065 - 43.620
52 Week Range17.100 - 69.568
Volume50,117
Avg. Volume102,031
Market Cap673.052M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.330
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est73.25
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments  

    Plan to Initiate Q4 2018 Rolling New Drug Application Submission to the U.S. Food and Drug Administration for UGN-101, Ahead of Initial Projection of Q1 2019. Initiated Phase 2 b Clinical Trial of UGN-102 ...

  • ACCESSWIRE6 days ago

    UroGen Pharma Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / UroGen Pharma Ltd. (NASDAQ: URGN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time. ...

  • GlobeNewswire12 days ago

    UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer

    RA’ANANA, Israel, and NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company today announced that Peter P. Pfreundschuh has been appointed as Chief Financial Officer (CFO) effective August 20, 2018.  Mr. Pfreundschuh brings to UroGen more than two decades of executive leadership experience in life sciences. Stephen Mullennix, who has served as UroGen’s Interim CFO since June 2018, will continue in his role as the Company’s Chief Operating Officer (COO).

  • GlobeNewswire13 days ago

    UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

    Conference Call and Webcast Scheduled for 8:30 AM ET. RA’ ANANA, Israel and NEW YORK, Aug. 07, 2018-- UroGen Pharma Ltd. today announced that it will report second quarter 2018 financial results on Tuesday, ...

  • GlobeNewswirelast month

    UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)

    RA’ANANA, Israel and NEW YORK, July 11, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it submitted to the U.S. Food and Drug Administration (FDA) an Investigational New Drug (IND) application for UGN-102 (VesiGel™, mitomycin gel for intravesical instillation) for the treatment of patients with low-grade non-muscle invasive bladder cancer (LG NMIBC) at the end of Q2 2018. If accepted, the Company expects to begin a Phase 2b clinical trial in the United States in Q3 2018.

  • GlobeNewswirelast month

    UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors  

    RA’ANANA, Israel and NEW YORK, July 10, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Shawn Cline Tomasello has been appointed to its Board of Directors. Ms. Tomasello is an industry expert who most recently served as Chief Commercial Officer at Kite, a Gilead Company. “We are thrilled to welcome Shawn to our Board of Directors.

  • GlobeNewswire2 months ago

    UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award

    RA’ANANA, Israel and NEW YORK, June 13, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Arie Belldegrun, MD, FACS, UroGen’s Chairman, will be honored with the prestigious EY Master Entrepreneur Award during the Entrepreneur of the Year 2018 Awards Gala on Thursday, June 14, 2018 in Los Angeles. The Master Entrepreneur Award is an exclusive designation by the Ernst & Young Entrepreneur of the Year judging panel bestowed upon an individual who distinctly outperforms the customary characteristics of an entrepreneur, exemplifies leadership at its best, drives a successful business or brand with notable longevity and greatly contributes to the local economy and community.

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and CoStar Group — Discovering Underlying Factors of Influence

    NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mesoblast ...

  • GlobeNewswire2 months ago

    UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance

    RA’ANANA, Israel, and NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced that Stephen Mullennix, UroGen’s Chief Operating Officer, will become Interim Chief Financial Officer, replacing Gary Titus. “Gary played an important role in the early stages of building UroGen and in particular the success of both our initial public offering and recent follow on offering, and we wish Gary success in his future endeavors,” said Ron Bentsur, Chief Executive Officer of UroGen.

  • GlobeNewswire3 months ago

    UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference

    RA’ ANANA, Israel and NEW YORK, May 29, 2018-- UroGen Pharma Ltd., a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, ...

  • Urogen Pharma Ltd. (URGN) Q1 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Urogen Pharma Ltd. (URGN) Q1 2018 Earnings Conference Call Transcript

    URGN earnings call for the period ending March 31, 2018.

  • Analysts Expect Breakeven For UroGen Pharma Ltd (NASDAQ:URGN)
    Simply Wall St.3 months ago

    Analysts Expect Breakeven For UroGen Pharma Ltd (NASDAQ:URGN)

    UroGen Pharma Ltd’s (NASDAQ:URGN): UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The US$922.25M market-cap company announced a latest loss of -US$20.82MRead More...

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: UroGen Pharma and Novartis

    NEW YORK, NY / ACCESSWIRE / April 4, 2018 / Shares of Novartis and UroGen both saw gains in Tuesday trading. UroGen saw its shares climb after announcing new data presentation from an interim analysis ...

  • Urogen Pharma Ltd (URGN) and CoStar Group Inc (CSGP) Are Among Wildcat Capital’s Top Winning Picks
    Insider Monkey6 months ago

    Urogen Pharma Ltd (URGN) and CoStar Group Inc (CSGP) Are Among Wildcat Capital’s Top Winning Picks

    Smaller hedge funds are usually better to follow in order to get investment ideas. Because these funds have less money that they have to invest, they are more nimble and can adjust their strategies faster in relation to broader market conditions. Moreover, smaller funds can invest in smaller companies and have a higher risk tolerance, […]